Deliver
Trace preparation, catheter or administration route, release and target arrival.
Real-work map · 11
Biomedical microrobot delivery
Evaluate access, release, navigation, imaging, payload stability, target delivery, clearance and rescue as one preclinical pathway.
Evidence statusResearch-frontier evidence framework · stage, material, control and retrieval validation requiredLast reviewed: 16 August 2026
11
FUURAA thesis
The useful unit is the complete intervention under a defined intended use—not movement inside a model.
Engineering map
Turn the title into engineering objects that can be observed, measured and reviewed.
Each layer states the boundary to establish and the evidence needed for the next decision.
Verify
Separate navigation success, payload release, biological effect and adverse response.
Resolve
Account for capsule, particles, degradation products, failed delivery and rescue.
Verification questions
Write the questions first, then decide whether a demo, test, pilot or operating record can answer them.
Each question needs an object, conditions, denominator, threshold and accountable decision owner.
- 01
What exact intended use and biological endpoint are proposed?
- 02
Which parts were tested in models versus animals?
- 03
Can imaging confirm location throughout the procedure?
- 04
What happens after incomplete release or failed retrieval?
Evidence to preserve
Enable the next reader to reconstruct conditions, results, failures and the decision.
A conclusion alone loses reviewability; raw records, configuration and exclusions matter too.
- 01
Evidence package 1
Intended-use and complete procedure map
- 02
Evidence package 2
Stage-separated navigation, delivery and biological outcomes
- 03
Evidence package 3
Material fate, rescue and adverse-response record
Scope boundary
State what this evidence still cannot be generalised to.
- 01
Preclinical navigation or delivery does not establish human safety, clinical benefit, approval or availability.
- 02
This is an engineering reading and decision framework; it does not replace application-specific risk assessment, conformity work, procurement acceptance or professional advice.
Sources and evidence status
Read standards scope, measurement evidence and application conclusions separately.
Source dates and review status remain visible; external sources open in a new tab.
01
ETH Zurich · Published 2025-11-13 · verified 2026-08-16
↗02Magnetically guided microrobots for targeted drug delivery
Integrates a soluble capsule, magnetic navigation, X-ray visibility, catheter release and drug delivery, with testing in vascular models and large animals.
Harbin Institute of Technology · Published 2025-10-31 · verified 2026-08-16
↗03Microscale fish-like robot swarms for drug-delivery research
Reports magnetic coordination, three-dimensional motion, aggregation and shape-adaptive attachment, including ultrasound-guided control in in-vitro models.
U.S. Food and Drug Administration · Final guidance 2014-06 · verified 2026-08-16
↗Considering whether an FDA-regulated product involves nanotechnology
Explains that dimension-dependent properties may require particular, product-specific attention to safety, effectiveness, quality and regulatory status.